Oxford Spin-Out Just Raised $300M to Rewrite the Rules of Drug Discovery

Jan de Vries · 2026-10-16

When a company spun out of a legendary Oxford lab announces an oversubscribed funding round, it's worth paying attention. OMass Therapeutics just closed a $300 million (€275 million) Series C round—and it's not just the size that's impressive. It's what they plan to do with it. ### The Who's Who of Investors The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings, with additional backing from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. Every existing investor also joined in, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. That's a serious vote of confidence. "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow," says Ros Deegan, CEO of OMass Therapeutics. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programs in endocrinology and immunology into the clinic." ### A Platform That Sees Drug Targets in Their Natural Habitat Founded in 2016, OMass was born from Professor Dame Carol Robinson's lab at the University of Oxford. The goal? To translate native mass spectrometry research into novel small molecule therapeutics against historically challenging targets. Their secret sauce is the OdyssION platform. It combines next-generation native mass spectrometry, novel biochemistry techniques, and custom chemistry to interrogate drug targets within their native ecosystems. Think of it as studying animals in the wild instead of a zoo—you get cell-system fidelity with cell-free precision. ### The Pipeline: OMS1620 and Beyond The proceeds will primarily support OMS1620, a potential best-in-class MC2 receptor antagonist, through Phase 2 clinical development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. OMS1620 is designed to increase receptor residency time and maintain activity, which could translate into better outcomes for patients. "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH," adds Evan Greif, Principal at Bain Capital Life Sciences. "We look forward to partnering with Ros and the team to support the Company's strategic and patient-first approach." ### A Wave of European Biotech Funding OMass' round is part of a broader surge in European therapeutics financing. In 2026 alone: - France's Bionyra Pharma secured $156 million (€143 million) for inflammatory diseases. - Denmark's Breye Therapeutics raised $74 million (€67.5 million) for its oral small-molecule pipeline. - UK-based STORM Therapeutics secured $52 million (€47.5 million), Microbiotica raised $46 million (€42 million), Mironid received $43.5 million (€39.9 million), and Alchemab Therapeutics secured $32 million (€29.3 million). - Netherlands' Laigo Bio added $6 million (€5.5 million). Together, these deals represent roughly $408 million (€374.7 million) in new financing during 2026—rising to $708 million (€649.7 million) when OMass' round is included. ### What This Means for Patients At its core, this funding is about bringing better medicines to people who need them. OMass is tackling conditions like CAH and Cushing's syndrome, where treatment options are limited. With this cash infusion, the company can push its lead program through Phase 2 and beyond. "Each of these candidates has the potential to address substantial unmet patient needs," says Max Klement, Partner at Novo Holdings. "We look forward to the Company's continuing progress." For those of us watching the European startup scene, OMass is a name to remember. It's not just about the money—it's about the science, the team, and the potential to make a real difference.